Phaseline

Targets › BLMH

BLMH (Bleomycin hydrolase): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Oncology, Other; next expected readout Jun 2031.

The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity. (UniProt, Q13867)

Open in Phaseline: the race on BLMH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institute of Oncology LjubljanaBleomycin Sulfate
DNA-damaging chemotherapy agent; internalization enhanced by electroporation
BLMHPhase 2Vulvar Cancer; Vascular MalformationsJun 2031

Conditions

Vulvar Cancer (1) Vascular Malformations (1)

Modalities

small molecule (1)

Companies

Institute of Oncology Ljubljana (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.